Cemdisiran Linked With Fewer Hospitalizations in Myasthenia Gravis Study
(MedPage Today) -- Cemdisiran, an investigational small interfering RNA (siRNA) therapeutic targeting complement component 5 (C5), led to fewer hospitalized myasthenia gravis patients compared with placebo, a prespecified exploratory analysis of...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.